RxDoctor Payments Data

Donald Yang, MD

Gastroenterology · Springfield, ORNPI 1023037306

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 24.8% of the total.

$1,352in general payments, 2019–2025

Across 41 payments — averaging $32.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335
  • Boston Scientific$219
  • Braintree Laboratories, Inc.$139
  • Sanofi$106
  • Ironwood Pharmaceuticals, Inc$96
  • E.r. Squibb & Sons, L.L.C.$86
  • plus $372 from 13 others

What the payments were for

  • Food & beverage$1,32198%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 75th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$68,003
Medicare patients
276
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin33$108,078
Mesalamine44$35,104
Mesalamine ErMesalamine23$9,895
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg286$7,578
SutabSod Sulf/Pot Chloride/Mag Sulf37$6,041
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates90$5,791
Budesonide EcBudesonide15$4,910
Ursodiol24$4,451
Budesonide DrBudesonide34$2,166
Esomeprazole Magnesium23$2,127
Azathioprine37$2,008
Omeprazole86$1,775
Pantoprazole Sodium62$1,559
Lactulose41$1,437
Famotidine60$1,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$108,07833 claims
Braintree Laboratories, Inc.Sutab$139$6,04137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →